{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T18:58:01Z","timestamp":1754161081687,"version":"3.41.2"},"reference-count":27,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Women treated for breast cancer often experience vulvovaginal atrophy (VVA). Vaginal oestrogen therapy (VET) can alleviate symptoms, but the impact on the risk of breast cancer recurrence is unclear. Based on a review of published studies of VET in patients with previous breast cancer, tamoxifen (TMX) users had no increase in breast cancer recurrence. In contrast, one study suggests a higher recurrence risk among aromatase inhibitor (AI) users compared to non-users. In conclusion, this review finds that VET can safely be used as VVA treatment in TMX users, whereas it should be used cautiously in AI users.<\/jats:p>","DOI":"10.61409\/v03240184","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T06:10:50Z","timestamp":1740982250000},"page":"1-7","source":"Crossref","is-referenced-by-count":0,"title":["Local oestrogen therapy and recurrence risk in women in endocrine adjuvant breast cancer therapy"],"prefix":"10.61409","author":[{"given":"Lisette Hvid","family":"Hovgaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie H.","family":"Tharin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Signe","family":"Borgquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pernille","family":"Ravn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"ref0","unstructured":"Sundhedsstyrelsen. Pakkeforl\u00f8b for brystkr\u00e6ft, For fagfolk, 2018. https:\/\/www.sst.dk\/-\/media\/Udgivelser\/2018\/Brystkraeft\/Pakkeforl%C3%B8b-for-brystkr%C3%A6ft-2018.ashx?sc_lang=da&hash=6D281953554BD4472CA64588D45935FD (16. feb 2024))"},{"key":"ref1","unstructured":"Systemisk behandling af brystkr\u00e6ft - II - pr\u00e6operativ og adjuverende systemisk behandling af tidlig brystkr\u00e6ft. DMCG. https:\/\/www.dmcg.dk\/siteassets\/retningslinjer\/godkendte-kr\/dbcg\/dbcg_praoperativ-og-adjuve-syst-bh-af-tidlig-brystkraft_v3.0_admgodk_211024.pdf DBCG vejledning.pdf (16. feb 2024)"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Jensen MB, Krarup JF, Palshof T et al. Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen breast cancer trial. Acta Oncol. 2018;57(1):26-30. https:\/\/doi.org\/10.1080\/0284186X.2017.1400179","DOI":"10.1080\/0284186X.2017.1400179"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Davies C, Godwin J, Gray R et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-784. https:\/\/doi.org\/10.1016\/S0140-6736(11)60993-8","DOI":"10.1016\/S0140-6736(11)60993-8"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Colleoni M, Luo W, Karlsson P et al. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19(1):127-138. https:\/\/doi.org\/10.1016\/S1470-2045(17)30715-5","DOI":"10.1016\/S1470-2045(17)30715-5"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Breast International Group (BIG) 1-98 Collaborative Group; Th\u00fcrlimann B, Keshaviah A, Coates AS et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353(26):2747-57. https:\/\/doi.org\/10.1056\/NEJMoa052258","DOI":"10.1056\/NEJMoa052258"},{"key":"ref6","unstructured":"Danske Multidisciplin\u00e6re Cancer Grupper. Systemisk behandling af brystkr\u00e6ft - II, pr\u00e6operativ og adjuverende systemisk behandling af tidlig brystkr\u00e6ft. C:\\Users\\jhm\\AppData\\Local\\Microsoft\\Windows\\INetCache\\Content.Outlook\\ZPWS23MU\\DBCG vejledning.pdf (16. feb 2024)"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"BIG 1-98 Collaborative Group; Mouridsen H, Giobbie-Hurder A, Goldhirsch A et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009;361(8):766-76. https:\/\/doi.org\/10.1056\/NEJMoa0810818","DOI":"10.1056\/NEJMoa0810818"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Wills S, Ravipati A, Venuturumilli P et al. Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator. J Oncol Pract. 2012;8(3):144-8. https:\/\/doi.org\/10.1200\/JOP.2011.000352","DOI":"10.1200\/JOP.2011.000352"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hickey M, Saunders C, Partridge A et al. Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol. 2008;19(10):1669-80. https:\/\/doi.org\/10.1093\/annonc\/mdn353","DOI":"10.1093\/annonc\/mdn353"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Bachmann G, Lobo RA, Gut R et al. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. Obstet Gynecol. 2008;111(1):67-76. https:\/\/doi.org\/10.1097\/01.AOG.0000296714.12226.0f","DOI":"10.1097\/01.AOG.0000296714.12226.0f"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Holmberg L, Anderson H; HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped. Lancet. 2004;363(9407):453-5. https:\/\/doi.org\/10.1016\/S0140-6736(04)15493-7","DOI":"10.1016\/S0140-6736(04)15493-7"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Holmberg L, Iversen OE, Rudenstam CM et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst. 2008;100(7):475-82. https:\/\/doi.org\/10.1093\/jnci\/djn058","DOI":"10.1093\/jnci\/djn058"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Moegele M, Buchholz S, Seitz S, Ortmann O. Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet. 2012;285(5):1397-402. https:\/\/doi.org\/10.1007\/s00404-011-2181-6","DOI":"10.1007\/s00404-011-2181-6"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Biglia N, Bounous VE, Sgro LG et al. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe hopes? Clin Breast Cancer. 2015;15(6):413-20. https:\/\/doi.org\/10.1016\/j.clbc.2015.06.005","DOI":"10.1016\/j.clbc.2015.06.005"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Santen RJ, Mirkin S, Bernick B, Constantine GD. Systemic estradiol levels with low-dose vaginal estrogens. Menopause. 2020;27(3):361-370. https:\/\/doi.org\/10.1097\/GME.0000000000001463","DOI":"10.1097\/GME.0000000000001463"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Mitchell CM, Larson JC, Crandall CJ et al. Association of vaginal estradiol tablet with serum estrogen levels in women who are postmenopausal: secondary analysis of a randomized clinical trial. JAMA Netw Open. 2022;5(11):e2241743. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.41743","DOI":"10.1001\/jamanetworkopen.2022.41743"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Notelovitz M, Funk S, Nanavati N, Mazzeo M. Estradiol absorption from vaginal tablets in postmenopausal women. Obstet Gynecol. 2002;99(4):556-62. https:\/\/doi.org\/10.1016\/s0029-7844(01)01385-0","DOI":"10.1016\/S0029-7844(01)01385-0"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Kendall A, Dowsett M, Folkerd E, Smith I. Caution: vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol. 2006;17(4):584-7. https:\/\/doi.org\/10.1093\/annonc\/mdj127","DOI":"10.1093\/annonc\/mdj127"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Melisko ME, Goldman ME, Hwang J et al. Vaginal testosterone cream vs estradiol vaginal ring for vaginal dryness or decreased libido in women receiving aromatase inhibitors for early-stage breast cancer: a randomized clinical trial. JAMA Oncol. 2017;3(3):313-319. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3904","DOI":"10.1001\/jamaoncol.2016.3904"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Pavlovi\u0107 RT, Jankovi\u0107 SM, Milovanovi\u0107 JR et al. The safety of local hormonal treatment for vulvovaginal atrophy in women with estrogen receptor-positive breast cancer who are on adjuvant aromatase inhibitor therapy: meta-analysis. Clin Breast Cancer. 2019;19(6):e731-e740. https:\/\/doi.org\/10.1016\/j.clbc.2019.07.007","DOI":"10.1016\/j.clbc.2019.07.007"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"O'Meara ES, Rossing MA, Daling JR et.al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst. 2001;93(10):754-62. https:\/\/doi.org\/10.1093\/jnci\/93.10.754","DOI":"10.1093\/jnci\/93.10.754"},{"issue":"1","key":"ref22","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/cmt.6.1.45.52","article-title":"A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer","volume":"6","author":"Dew","year":"2003","unstructured":"Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric. 2003;6(1):45-52.","journal-title":"Climacteric"},{"issue":"2","key":"ref23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/cmt.5.2.151.155","article-title":"Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study","volume":"5","author":"Dew","year":"2002","unstructured":"Dew JE, Wren BG, Eden JA. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study. Climacteric. 2002;5(2):151-5.","journal-title":"Climacteric"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Le Ray I, Dell'Aniello S, Bonnetain F et al. Local estrogen therapy and risk of breast cancer recurrence among hormone-treated patients: a nested case-control study. Breast Cancer Res Treat. 2012;135(2):603-9. https:\/\/doi.org\/10.1007\/s10549-012-2198-y","DOI":"10.1007\/s10549-012-2198-y"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Sund M, Garmo H, Andersson A et al. Estrogen therapy after breast cancer diagnosis and breast cancer mortality risk. Breast Cancer Res Treat. 2023;198(2):361-368. https:\/\/doi.org\/10.1007\/s10549-023-06871-w","DOI":"10.1007\/s10549-023-06871-w"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Cold S, Cold F, Jensen MB et al. Systemic or vaginal hormone therapy after early breast cancer: a Danish observational cohort study. J Natl Cancer Inst. 2022;114(10):1347-1354. https:\/\/doi.org\/10.1093\/jnci\/djac112","DOI":"10.1093\/jnci\/djac112"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T13:39:00Z","timestamp":1753709940000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V03240184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":27,"URL":"https:\/\/doi.org\/10.61409\/v03240184","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,3,3]]}}}